Non-small Cell Lung Cancer (NSCLC)NCT06448793
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
An observational study of Non-small Cell Lung Cancer (NSCLC), run by Bristol-Myers Squibb at 1 site in United Kingdom.
Trial summary
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-small Cell Lung Cancer (NSCLC)
- What is being tested?
- Approved Non-small Cell Lung Cancer (NSCLC) therapies
- How many people
- 650 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 25 Nov 2024to 31 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults participants with a diagnosis of resectable NSCLC and physicians treating patients with resectable NSCLC residing in US, Germany or Japan.
Who may be able to join
- Patients
- Aged ≥18 years at the time of enrollment in the study
- Resident of the US, Germany, or Japan
- Able to read, speak, and understand English, German or Japanese
- Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)
- Physicians
Show all 9Show fewer
- Resident of the US, Germany, or Japan
- Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology
- Treated at least three new patients with resectable NSCLC in the past year
Who cannot join
- Patients
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
- Being diagnosed with another malignancy alongside NSCLC
- Not willing to be audio-recorded during the interview
- Physicians
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
- Not willing to be audio-recorded during the interview
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Being tested
- Approved Non-small Cell Lung Cancer (NSCLC) therapies
- Keywords
- Non-small Cell Lung Cancer (NSCLC)
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Approved Non-small Cell Lung Cancer (NSCLC) therapiesDrug
As prescribed by treating physician
| Study group | Role | What they receive |
|---|---|---|
| Patients with a diagnosis of resectable non-small cell lung cancer (NSCLC) | Not described Receives: Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies | |
| Physicians currently treating resectable non-small cell lung cancer (NSCLC) patients | Not described Receives: Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies |
What is being measured
The primary outcome is the main question the study is designed to answer.
Responses to qualitative interview questions
Interview questions designed to gather insights into diagnosis, symptoms, current treatments, perspectives on treatment features and test for mock preferences tasks. The interview will take 15 minutes to complete.
Measured: Day 1
Patient sociodemographic
Measured: Day 1
Patient clinical characteristics
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jun 2024
- Study start25 Nov 2024
- Primary completion31 Oct 2025
- Study completion31 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-small Cell Lung Cancer (NSCLC)Studies of the same condition, open and under way.
- More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 650 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06448793
- Sponsor's protocol ID
- CA209-1384
- Status last verified
- Jul 2026
- First submitted
- 4 Jun 2024
- Last updated
- 4 Aug 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments
- ClinicalTrials.gov ID
- NCT06448793
- Acronym / sponsor ID
- CA209-1384
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Keywords
- Non-small Cell Lung Cancer (NSCLC)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 650 participants (actual)
- Lead sponsor
- Bristol-Myers SquibbIndustry (pharma, biotech, devices)
- Study start
- 25 Nov 2024 (actual)
- Primary completion
- 31 Oct 2025 (actual)
- Study completion
- 31 Oct 2025 (actual)
- First posted
- 7 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with a diagnosis of resectable non-small cell lung cancer (NSCLC) | – | Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies |
| Physicians currently treating resectable non-small cell lung cancer (NSCLC) patients | – | Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults participants with a diagnosis of resectable NSCLC and physicians treating patients with resectable NSCLC residing in US, Germany or Japan.
Key inclusion criteria (9 listed)
- Patients
- Aged ≥18 years at the time of enrollment in the study
- Resident of the US, Germany, or Japan
- Able to read, speak, and understand English, German or Japanese
- Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)
Key exclusion criteria (7 listed)
- Patients
- Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
- Being diagnosed with another malignancy alongside NSCLC
- Not willing to be audio-recorded during the interview
- Physicians
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Approved Non-small Cell Lung Cancer (NSCLC) therapiesAs prescribed by treating physician | Drug | Patients with a diagnosis of resectable non-small cell lung cancer (NSCLC), Physicians currently treating resectable non-small cell lung cancer (NSCLC) patients |
Primary outcome
Responses to qualitative interview questions
Time frame: Day 1
Interview questions designed to gather insights into diagnosis, symptoms, current treatments, perspectives on treatment features and test for mock preferences tasks. The interview will take 15 minutes to complete.
Patient sociodemographic
Time frame: Day 1
Patient clinical characteristics
Time frame: Day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2026.
- BMS Clinical Trial InformationLink provided by the sponsor.
- FDA Safety Alerts and RecallsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Non-small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 3
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Carcinoma, Non-Small-Cell Lung
RecruitingPhase 1
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Solid Tumor, Non-Small-Cell Lung Cancer
RecruitingPhase 1/2
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Carcinoma, Non-Small-Cell Lung
RecruitingPhase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Active, not recruitingPhase 3
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb study director
Bristol-Myers Squibb
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non-small Cell Lung Cancer (NSCLC), run by Bristol-Myers Squibb at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Responses to qualitative interview questions (time frame: Day 1). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2026.